Authors: Michallet, A.S., Dilhuydy, M.S., Subtil, F., Rouille, V., Mahe, B., Laribi, K., Villemagne, Salles, G.A., Tournilhac, O., Delmer, A.J., Portois, C., Pegourie, Leblond, Tomowiak, De Guibert, S., Orsini, Banos, A., Carassou, P., Cartron, G., FORNECKER, L.M., Ysebaert, Loic, Dartigeas, Truchan, M., Vilque, J.P., Aurran, T., Cymbalista, Lepretre, Levy, M.V., Nguyen-Khac, Le Garff-Tavernier, Aanaei, Ticchioni, Letestu, R., Feugier
Venue: Blood
Type: Publication
Abstract: Introduction In previously untreated, medically fit patients with chronic lymphocytic leukaemia (CLL) and no 17p deletion, there is current research interest in improving survival outcomes and potentially sparing some patients from the standard 6 cycles of fludarabine, cyclophosphamide and rituximab (FCR). The phase II ICLL-07 (NCT02666898) trial, conducted by the French Innovative Leukemia Organization (FILO), aimed to explore the efficacy of obinutuzumab and ibrutinib treatment induction for 9 months, followed by a minimal residual disease (M...
(read more)
Topics: 
Internal medicine
Oncology
Surgery
Loading (it may take a couple of seconds)...
Loading (it may take a couple of seconds)...